Published in JAMA on October 12, 2011
S0000 Selenium and Vitamin E in Preventing Prostate Cancer (SELECT) | NCT00006392
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
Oxidative stress inhibits distant metastasis by human melanoma cells. Nature (2015) 3.87
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol (2015) 2.06
Regulation of Nrf2-an update. Free Radic Biol Med (2013) 1.81
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol (2013) 1.81
Military report more complementary and alternative medicine use than civilians. J Altern Complement Med (2013) 1.69
Health-promoting components of fruits and vegetables in the diet. Adv Nutr (2013) 1.68
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
The relationship between nutrition and prostate cancer: is more always better? Eur Urol (2012) 1.66
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Dietary supplements and cancer prevention: balancing potential benefits against proven harms. J Natl Cancer Inst (2012) 1.60
Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst (2014) 1.44
Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. J Clin Oncol (2016) 1.42
Do environmental factors modify the genetic risk of prostate cancer? Cancer Epidemiol Biomarkers Prev (2014) 1.42
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Periconceptional intake of vitamins and fetal death: a cohort study on multivitamins and folate. Int J Epidemiol (2014) 1.38
The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int (2014) 1.34
Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev (2013) 1.28
Glutathione: new roles in redox signaling for an old antioxidant. Front Pharmacol (2014) 1.25
Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol (2015) 1.24
Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology (2015) 1.21
Mitochondrial reactive oxygen species and cancer. Cancer Metab (2014) 1.20
Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open (2012) 1.20
Cancer chemoprevention: a rapidly evolving field. Br J Cancer (2013) 1.20
Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl (2012) 1.19
Selenium for preventing cancer. Cochrane Database Syst Rev (2014) 1.17
Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci (2013) 1.15
Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol (2013) 1.15
Vitamin and mineral supplements: do we really need them? Int J Prev Med (2012) 1.14
Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol (2016) 1.09
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 1.08
Glutathione and mitochondria. Front Pharmacol (2014) 1.08
How does the macula protect itself from oxidative stress? Mol Aspects Med (2012) 1.06
The neglected significance of "antioxidative stress". Oxid Med Cell Longev (2012) 1.06
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Strategies for reducing or preventing the generation of oxidative stress. Oxid Med Cell Longev (2011) 1.03
The antioxidant paradox: less paradoxical now? Br J Clin Pharmacol (2013) 1.03
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) (2012) 1.01
The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res (2012) 1.01
Does vitamin E prevent or promote cancer? Cancer Prev Res (Phila) (2012) 1.01
A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nutr Health Aging (2013) 1.00
Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate (2013) 0.99
Major metabolite of F2-isoprostane in urine may be a more sensitive biomarker of oxidative stress than isoprostane itself. Am J Clin Nutr (2012) 0.98
δ- and γ-tocopherols, but not α-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 rats. Cancer Prev Res (Phila) (2012) 0.98
Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med (2015) 0.98
Options for basing Dietary Reference Intakes (DRIs) on chronic disease endpoints: report from a joint US-/Canadian-sponsored working group. Am J Clin Nutr (2016) 0.97
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog (2011) 0.97
Toward a new philosophy of preventive nutrition: from a reductionist to a holistic paradigm to improve nutritional recommendations. Adv Nutr (2014) 0.96
Disruption of the selenocysteine lyase-mediated selenium recycling pathway leads to metabolic syndrome in mice. Mol Cell Biol (2012) 0.96
Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care (2012) 0.96
Total and individual antioxidant intake and risk of epithelial ovarian cancer. BMC Cancer (2012) 0.95
Haptoglobin genotype and its role in diabetic cardiovascular disease. J Cardiovasc Transl Res (2012) 0.94
Natural-source d-α-tocopheryl acetate inhibits oxidant stress and modulates atopic asthma in humans in vivo. Allergy (2012) 0.93
Antioxidant vitamins and mineral supplementation, life span expansion and cancer incidence: a critical commentary. Eur J Nutr (2012) 0.93
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol (2014) 0.93
A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer--the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis (2014) 0.93
Can selenium levels act as a marker of colorectal cancer risk? BMC Cancer (2013) 0.93
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
Serum α-tocopherol and γ-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study. PLoS One (2012) 0.93
Moving a randomized clinical trial into an observational cohort. Clin Trials (2012) 0.93
Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med (2015) 0.92
Toward understanding success and failures in the use of selenium for cancer prevention. Antioxid Redox Signal (2013) 0.91
Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal (2013) 0.91
Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression. Oxid Med Cell Longev (2015) 0.91
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc (2015) 0.90
Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med (2013) 0.90
Addressing nutritional gaps with multivitamin and mineral supplements. Nutr J (2014) 0.89
Dietary antioxidants and prostate cancer: a review. Nutr Cancer (2013) 0.89
Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination. J Natl Cancer Inst (2015) 0.89
Biomarkers in nutrition: new frontiers in research and application. Ann N Y Acad Sci (2013) 0.89
Chemoprevention of prostate cancer: an updated view. World J Urol (2012) 0.89
Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol (2013) 0.88
Biofortification and phytoremediation of selenium in China. Front Plant Sci (2015) 0.88
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.88
Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutrients (2013) 0.88
Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol (2014) 0.87
Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. Am J Clin Nutr (2015) 0.86
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget (2016) 0.86
Vitamin E protects against lipid peroxidation and rescues tumorigenic phenotypes in cowden/cowden-like patient-derived lymphoblast cells with germline SDHx variants. Clin Cancer Res (2012) 0.86
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. J Urol (2012) 0.86
Natural products for cancer prevention. Semin Oncol Nurs (2012) 0.86
Expression of the α-tocopherol transfer protein gene is regulated by oxidative stress and common single-nucleotide polymorphisms. Free Radic Biol Med (2012) 0.86
Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed. J Pers Med (2015) 0.86
Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival. Cancer Epidemiol Biomarkers Prev (2014) 0.85
The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial. Eur J Nutr (2013) 0.85
Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist (2012) 0.85
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients. PLoS One (2012) 0.85
Complementary or alternative medicine in cancer care-myths and realities. Nat Rev Clin Oncol (2013) 0.85
Vitamin E reverses multidrug resistance in vitro and in vivo. Cancer Lett (2013) 0.84
Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention. Exp Cell Res (2013) 0.84
Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol (2015) 0.84
Cancer drug resistance: redox resetting renders a way. Oncotarget (2016) 0.84
Novel metabolites and roles for α-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics. Am J Clin Nutr (2012) 0.84
Selenium induces a multi-targeted cell death process in addition to ROS formation. J Cell Mol Med (2014) 0.84
Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. JAMA Ophthalmol (2015) 0.84
Is selenium a potential treatment for cancer metastasis? Nutrients (2013) 0.84
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 21.37
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med (1994) 5.98
Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst (1996) 5.63
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet (2010) 2.78
Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology (2011) 2.68
Brief communication: The prevalence of high intake of vitamin E from the use of supplements among U.S. adults. Ann Intern Med (2005) 2.39
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Factorial design considerations. J Clin Oncol (2002) 1.66
Vitamin E supplementation and cataract: randomized controlled trial. Ophthalmology (2004) 1.48
Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ (2002) 1.41
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) (2011) 1.38
Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol (2011) 1.18
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Lung cancer. N Engl J Med (2008) 13.49
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62